Consider the January issue of GEN a lofty prospect from which to survey, far and wide, the multifarious biopharma landscape. Direct your gaze toward the issue’s 2024 Trends section, and you’ll find perspectives on single-cell sequencing, multiomics, cell and gene manufacturing, and AI-driven drug development. Your guides in these articles are practitioners of what they preach. Yet other expanses are revealed by our own staff writers. Senior business editor Alex Philippidis has two offerings: an “A-List” of the top 25 biotech companies of 2024, and a summary of recent site selection deals. Deputy editor in chief Julianna LeMieux discusses what we can expect from next-generation sequencing in 2024. And our evp of strategic development, Kevin Davies, discusses the landmark FDA decision to approve the first CRISPR therapy for sickle cell disease. Finally, to round out the 360° view afforded by this issue of GEN, there are articles on laboratory automation and smart biomanufacturing.